+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Attention deficit Hyperactivity Disorder (ADHD) Drugs Market 2019-2023 - Product Image

Global Attention deficit Hyperactivity Disorder (ADHD) Drugs Market 2019-2023

  • ID: 4772965
  • Report
  • May 2019
  • Region: Global
  • 127 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Eli Lilly and Co.
  • NEOS Therapeutics Inc.
  • MORE
The rising incidence rate of ADHD among children is one of the critical factors that will trigger the growth of the attention deficit hyperactivity disorder drugs market. The expansion of the patient pool with positive ADHD symptoms is fueling the demand for ADHD therapies. As per the CDC, in 2016. Approximately 9.4% of children aged 2-17 years were diagnosed with ADHD. Thus, a significant patient pool (aged between 12 and 17 years) rely on medications. This is expected to rise further with the increasing prevalence of the disease, thereby contributing to the growth of the market during the forecast period. Analysts have predicted that the attention deficit hyperactivity disorder (ADHD) drugs market will register a CAGR of almost 6% by 2023.

Market Overview

Rising government support

The global ADHD drugs market is currently witnessing an increase in the number of government initiatives to promote the awareness of the disease and to fund drug development in the area of mental health therapeutics. Additionally, the Centers for Disease Control and Prevention (CDC) supports the National Resource Center (NRC) on ADHD, a program designed to help children and adults with ADHD. The NRC program provides information, resources, and advice to parents on how to help their children with ADHD. Thus, the rising government support to help people with ADHD is expected to drive the growth of the market during the forecast period.

Lack of patient compliance with ADHD treatment

The pharmacological (medications) treatment with neuro-stimulant drugs is considered as the gold standard for the treatment of ADHD in children and adults. However, the multiple dosing regimens associated with neuro-stimulant drugs, such as methylphenidate and amphetamine, and the timely dosing and long duration of the treatment are leading to a decrease in the patient compliance with these drugs. This leads to a decline in the consumption of ADHD drugs, thereby impeding the growth of the market.

Competitive Landscape

The market appears to be highly fragmented. The presence of several companies, including Johnson & Johnson Services Inc. and NEOS Therapeutics Inc. makes the competitive environment quite intense. Factors such as the rising incidence rate of ADHD among children and the increasing government support will provide considerable growth opportunities to attention deficit hyperactivity disorder drugs manufactures. Amneal Pharmaceuticals Inc., Eli Lilly and Co., and Takeda Pharmaceutical Co. Ltd. are some of the major companies covered in this report.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Eli Lilly and Co.
  • NEOS Therapeutics Inc.
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • Stimulants - Market size and forecast 2018-2023
  • Non-stimulants - Market size and forecast 2018-2023
  • Market opportunity by product
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Amneal Pharmaceuticals Inc.
  • Eli Lilly and Co.
  • Johnson & Johnson Services Inc.
  • NEOS Therapeutics Inc.
  • Takeda Pharmaceutical Co. Ltd.
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
PART 15: EXPLORE

List of Exhibits:
Exhibit 01: Global central nervous system (CNS) disorders drugs market
Exhibit 02: Segments of global central nervous system (CNS) disorders drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Product - Market share 2018-2023 (%)
Exhibit 18: Comparison by product
Exhibit 19: Stimulants - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Stimulants - Year-over-year growth 2019-2023 (%)
Exhibit 21: Non-stimulants - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Non-stimulants - Year-over-year growth 2019-2023 (%)
Exhibit 23: Market opportunity by product
Exhibit 24: Customer landscape
Exhibit 25: Market share by geography 2018-2023 (%)
Exhibit 26: Geographic comparison
Exhibit 27: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 28: Mental illness scenario in the US in 2016
Exhibit 29: CDC statistics on the incidence rate of ADHD and other disorder among children aged 2-17 years in 2016
Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
Exhibit 31: Top 3 countries in North America
Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in Europe
Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Asia
Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: Prevalence rate of mental disorder in the Australian population aged 4 to 17 years, 2016
Exhibit 40: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 41: Top 3 countries in ROW
Exhibit 42: Key leading countries
Exhibit 43: Market opportunity
Exhibit 44: ADHD scenario in the US in 2016
Exhibit 45: ADHD treatment scenario by age group
Exhibit 46: Adoption towards pharmacological therapy among ADHD children in the US, 2011
Exhibit 47: Prevalence scenario of AMI in the US, 2017
Exhibit 48: Prevalence scenario of SMI in the US, 2017
Exhibit 49: Factors leading to noncompliance with drug therapy
Exhibit 50: Management of side-effects associated with ADHD medication
Exhibit 51: Impact of drivers and challenges
Exhibit 52: Vendor landscape
Exhibit 53: Landscape disruption
Exhibit 54: Vendors covered
Exhibit 55: Vendor classification
Exhibit 56: Market positioning of vendors
Exhibit 57: Amneal Pharmaceuticals Inc. - Vendor overview
Exhibit 58: Amneal Pharmaceuticals Inc. - Business segments
Exhibit 59: Amneal Pharmaceuticals Inc. - Organizational developments
Exhibit 60: Amneal Pharmaceuticals Inc. - Segment focus
Exhibit 61: Amneal Pharmaceuticals Inc. - Key offerings
Exhibit 62: Amneal Pharmaceuticals Inc. - Key customers
Exhibit 63: Eli Lilly and Co. - Vendor overview
Exhibit 64: Eli Lilly and Co. - Business segments
Exhibit 65: Eli Lilly and Co. - Organizational developments
Exhibit 66: Eli Lilly and Co. - Geographic focus
Exhibit 67: Eli Lilly and Co. - Segment focus
Exhibit 68: Eli Lilly and Co. - Key offerings
Exhibit 69: Eli Lilly and Co. - Key customers
Exhibit 70: Johnson & Johnson Services Inc. - Vendor overview
Exhibit 71: Johnson & Johnson Services Inc. - Business segments
Exhibit 72: Johnson & Johnson Services Inc. - Organizational developments
Exhibit 73: Johnson & Johnson Services Inc. - Geographic focus
Exhibit 74: Johnson & Johnson Services Inc. - Segment focus
Exhibit 75: Johnson & Johnson Services Inc. - Key offerings
Exhibit 76: Johnson & Johnson Services Inc. - Key customers
Exhibit 77: NEOS Therapeutics Inc. - Vendor overview
Exhibit 78: NEOS Therapeutics Inc. - Business segments
Exhibit 79: NEOS Therapeutics Inc. - Organizational developments
Exhibit 80: NEOS Therapeutics Inc. - Key offerings
Exhibit 81: NEOS Therapeutics Inc. - Key customers
Exhibit 82: Takeda Pharmaceutical Co. Ltd. - Vendor overview
Exhibit 83: Takeda Pharmaceutical Co. Ltd. - Business segments
Exhibit 84: Takeda Pharmaceutical Co. Ltd. - Organizational developments
Exhibit 85: Takeda Pharmaceutical Co. Ltd. - Geographic focus
Exhibit 86: Takeda Pharmaceutical Co. Ltd. - Key offerings
Exhibit 87: Takeda Pharmaceutical Co. Ltd. - Key customers
Exhibit 88: Validation techniques employed for market sizing
Exhibit 89: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 5

FEATURED COMPANIES

  • Eli Lilly and Co.
  • NEOS Therapeutics Inc.
  • MORE
The analyst recognizes the following companies as the key players in the global attention deficit hyperactivity disorder (ADHD) drugs market: Amneal Pharmaceuticals Inc., Eli Lilly and Co., Johnson & Johnson Services Inc., NEOS Therapeutics Inc., and Takeda Pharmaceutical Co. Ltd.

Commenting on the report, an analyst from the team said: “The latest trend gaining momentum in the market is the rising off-label use of ADHD medications among children.”

According to the report, one of the major drivers in this market is the rising government support.

Further, the report states that one of the major factors hindering the growth of this market is the side-effects associated with ADHD therapeutics.

The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
4 of 5
  • Amneal Pharmaceuticals Inc.
  • Eli Lilly and Co.
  • Johnson & Johnson Services Inc.
  • NEOS Therapeutics Inc.
  • Takeda Pharmaceutical Co. Ltd.
Note: Product cover images may vary from those shown
5 of 5

Loading
LOADING...

Adroll
adroll